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To the Editor: As the world strug-
gles with the challenges of inﬂ  uenza A 
pandemic (H1N1) 2009, it is clear that 
treatment options for critically ill in-
fected patients are suboptimal because 
deaths continue to be reported in oth-
erwise young and healthy patients. Ex-
tracorporeal membrane oxygenation 
(ECMO) is an established therapeutic 
option for patients with medically re-
fractory cardiogenic or respiratory fail-
ure. We describe the successful use of 
ECMO in a patient with complicated 
pneumonia and inﬂ  uenza A pandemic 
(H1N1) 2009 virus infection. 
Our patient, a 21-year-old woman 
who was 4 months postpartum, had 
poorly controlled insulin-dependent 
diabetes (hemoglobin A1C level 13.2 
mg/dL). She sought treatment at an-
other hospital after 3 days of respira-
tory symptoms, a productive cough af-
ter working in her garden, and a fever 
>103°F. Her condition rapidly dete-
riorated, and she required mechanical 
ventilation, vasoactive medications, 
and drotecogin-α (Xigris; Eli Lilly and 
Company, Indianapolis, IN, USA) for 
profound shock. 
The patient was then transferred 
to Ohio State University Medical 
Center on August 24, 2009; at admis-
sion she exhibited hypotension (83/43 
mm Hg) and tachycardia (159 bpm), 
despite having received high doses of 
vasoactive medications (norepineph-
rine 1.0 μg/kg/min, phenylephrine 2.0 
μg/kg/min). A transthoracic echocar-
diograph showed severe biventricular 
failure (ejection fraction 5%–10%); 
peak tropinin level was 6 mg/dL. Arte-
rial blood gas conﬁ  rmed metabolic ac-
idosis (pH 7.12, partial carbon dioxide 
pressure [pCO2] 48 mm Hg, pO2 117 
mm Hg, HCO3 15.3 mmol/L). Despite 
ﬂ  uid resuscitation and administration 
of epinephrine (0.06 μg/kg/min), her 
condition failed to improve, and she 
was given femoral vein–femoral ar-
tery ECMO.
A comprehensive search for 
infectious causes was undertaken. 
Treatment with broad-spectrum em-
piric antimicrobial drugs such as 
linezolid (Pﬁ   zer, Inc, New York, 
NY, USA), piperacillin/tazobactam 
(Wyeth, Madison, NJ, USA), and 
doxycycline (Pﬁ   zer, Inc) and the 
antiviral drug oseltamivir (Tamiﬂ  u; 
Roche Laboratories Inc., Nutley, NJ, 
USA), 150 mg 2×/d, was started. Re-
spiratory cultures were positive for 
methicillin-sensitive  Staphylococcus 
aureus and Aspergillus glaucus. Naf-
cillin and voriconazole were added 
to the treatment regimen. PCR of a 
bronchoalveolar lavage specimen 
later identiﬁ   ed pandemic (H1N1) 
2009 virus. The patient was weaned 
from ECMO on hospital day (HD) 
10 and extubated on HD11. Repeat 
cardiovascular evaluation showed 
normal biventricular function and no 
coronary disease. She was discharged 
from hospital for rehabilitation on 
September 15, 2009 (HD 22), with an 
oxygen saturation of 98% on room air 
and is now fully recovered.
The use of ECMO is an estab-
lished option for patients with medi-
cally refractory acute and reversible 
cardiopulmonary failure (1–3) (Table). 
For isolated respiratory failure, veno–
veno support can be used by femoral 
vein to femoral vein or femoral vein to 
right internal jugular vein cannulation. 
With concomitant cardiogenic shock, 
veno–arterial cannulation may be re-
quired with cannulation of the right 
internal jugular or femoral vein for 
outﬂ  ow, and for inﬂ  ow, the femoral 
artery directly or the axillary artery by 
a surgically placed side graft. Central 
venous (right atrium) and arterial (as-
cending aorta) cannulation is an option 
but requires median sternotomy.
This case is not the ﬁ  rst reported 
use of ECMO for respiratory failure 
secondary to viral pneumonia (4),
and recently, ECMO was used with 
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Table. Relative indications and contraindications for extracorporeal membrane 
oxygenation*
Characteristics
Cardiac support (1)
  Cardiac index <2.2 L/min/m
2
  Systolic pressure <90 mm Hg 
  Pulmonary capillary wedge pressure >20 mm Hg 
  Central venous pressure >20 mm Hg  
  Two high-dose inotropic medications (Including intraaortic counter pulsation) 
Respiratory support (2)
  Murray score >3.0 based on: 
  P a O 2/FiO2 ratio 
    No. infiltrated quadrants on chest radiograph 
    Positive end-expiratory pressure requirement  
 Pulmonary  compliance 
 Uncompensated  hypercapnea  (pH<7.2) 
Contraindications 
  Advancing age (>70 y) 
  Prolonged mechanical ventilation (>7 d) 
  Surgically correctable causes 
  Pneumothorax,  effusions,  endoluminal  obstructions 
    Intracardiac shunts, valvular pathology, incomplete revascularization 
  Medical problems incompatible with prolonged survival 
  Advanced  malignancies 
  Contraindications  to  anticoagulation 
    Irreversible neurologic dysfunction (dementia, stroke, hemorrhage) 
  Medical futility (i.e., prolonged CPR, multiorgan failure) 
*CPR, cardiopulmonary resuscitation; PaO2, partial pressure of oxygen in arterial blood; F1O2,
concentration of inspired oxygen. LETTERS
limited success for complications of 
pandemic (H1N1) 2009 (5). Its broad-
er use in treating critically ill patients 
has been limited, however, because 
ECMO requires substantial institution-
al and multidisciplinary commitment 
for implementation and is typically 
only available at major medical centers 
offering cardiovascular surgery.
Although we cannot say speciﬁ  -
cally why our patient survived, clearly, 
aggressive and comprehensive empiric 
treatment, physiologic support, and 
close multidisciplinary communication 
were vital to managing the condition of 
this critically ill patient. ECMO may 
have assisted in organ recovery and pa-
tient survival. However, further studies 
should be conducted to critically evalu-
ate ECMO in the armamentarium of 
therapeutic options for severe pandem-
ic (H1N1) 2009 respiratory failure. 
Michael S. Firstenberg, 
Danielle Blais, Louis B. Louis, 
Kurt B. Stevenson, 
Benjamin Sun, 
and Julie E. Mangino
Author afﬁ   liation: Ohio State University 
Medical Center, Columbus, Ohio, USA
DOI: 10.3201/eid1512.091434
References
  1.   Samuels LE, Kaufman MS, Thomas MP, 
Holmes EC, Brockman SK, Wechsler AS. 
Pharmacological criteria for ventricular 
assist device insertion following post-
cardiotomy shock: experience with the 
ABIOMED BVS system. J Card Surg. 
1999;14:288–93. DOI: 10.1111/j.1540-
8191.1999.tb00996.x
  2.   Thalanany MM, Mugford M, Hibbert C, 
Cooper NJ, Truesdale A, Robinson S, et 
al.; CESAR Trial Group. Methods of data 
collection and analysis for the economic 
evaluation alongside a national, multi-
centre trial in the UK: conventional ven-
tilation or ECMO for severe adult respira-
tory failure (CESAR). BMC Health Serv 
Res. 2008;8:94. DOI: 10.1186/1472-6963
-8-94
    3.   Bartlett RH, Roloff DW, Custer JR, 
Younger JG, Hirschl RB. Extracorporeal 
life support: the University of Michigan 
experience. JAMA. 2000;283:904–8. 
DOI: 10.1001/jama.283.7.904
  4.   Lefrak EA, Steven PM, Pitha J, Balsinger 
E, Noon GP, Mayor HD. Extracorporeal 
membrane oxygenation for fulminary in-
ﬂ  uenza pneumonia. Chest. 1974;66:385–8. 
DOI: 10.1378/chest.66.4.385
    5.   Centers for Disease Control and Pre-
vention. Intensive-care patients with 
severe novel inﬂ   uenza A (H1N1) virus 
infection—Michigan, June 2009. MMWR 
Morb Mortal Wkly Rep. 2009;58:749–52.
Address for correspondence: Michael S. 
Firstenberg, Division of Cardiothoracic 
Surgery, Ohio State University Medical Center, 
410 W 10th Ave, N817 Doan Hall, Columbus, 
OH 43212, USA; email: michael.ﬁ  rstenberg@
osumc.edu
Respiratory 
Disease in Adults 
during Pandemic 
(H1N1) 2009 
Outbreak, 
Argentina
To the Editor: We report a mild 
to moderate respiratory disease in 
patients seeking treatment for in-
ﬂ   uenza-like illness (ILI) within the 
ﬁ  rst 8 weeks of an outbreak of inﬂ  u-
enza A pandemic (H1N1) 2009 virus 
(pandemic [H1N1] 2009) infection 
in the Province of Buenos Aires. The 
ﬁ  rst cases of pandemic (H1N1) 2009 
in Argentina were reported in early 
May 2009 in travelers returning from 
Mexico and the United States. In mid-
June, a sharp increase was reported 
in the number of patients with acute 
respiratory symptoms who were seek-
ing treatment in emergency rooms. By 
July 9th, the Argentinean Ministry of 
Health had conﬁ  rmed 2,677 cases and 
82 deaths; most of those infected were 
residents of Buenos Aires and the sur-
rounding area (1). When the World 
Health Organization raised the pan-
demic level to 6, >80% of circulating 
inﬂ  uenza A virus in Argentina was sub-
type H1N1 (2). At the Hospital Central 
de San Isidro, a tertiary hospital of 160 
beds in the Province of Buenos Aires, 
initial clinical evaluation of patients 
with ILI symptoms included physical 
examination and, eventually, chest ra-
diograph and pulse oximetry. Because 
diagnostic resources were limited, pa-
tients with ILI were eligible to receive 
oseltamivir with no prior sampling for 
respiratory pathogens. A standardized 
form was used for prescription and 
data collection, including demographic 
data, history of inﬂ  uenza vaccination, 
date symptoms began, and coexisting 
illnesses. From June 16 to July 5, a 
total of 2,135 patients with ILI were 
evaluated. The age of patients ranged 
from 14 to 82 years of age (median, 
35 years); 854 patients (40 %) were 
male. Because of lower respiratory 
disease, a total of 166 (8%) of 2,135 
patients were admitted to the internal 
medicine ward (n = 139) or to the in-
tensive care unit (n = 27). At admis-
sion, patients had >1 of the following: 
diffuse pulmonary inﬁ  ltrates, room air 
oxygen saturation <95%, crackles on 
auscultation. Other clinical manifes-
tations were not statistically different 
from those already reported in patients 
with pandemic (H1N1) 2009 in the 
United States, including cough, fever, 
and sore throat (3). The most common 
radiology pattern was basal, and bi-
lateral interstitial inﬁ  ltrates were con-
sistent with primary viral pneumonia. 
Notably, some patients had clinical 
radiologic dissociation characterized 
by cough and pulmonary inﬁ  ltrates in 
the absence of fever. Median time of 
hospitalization was 36 hours (range 
1–25 days). No signiﬁ  cant differences 
were observed between the groups 
of patients that were admitted versus 
outpatients in terms of age, sex, num-
ber of days from initiation of fever 
to  ﬁ  rst hospital visit, and history of 
inﬂ  uenza vaccination. A total of 163 
(98%) of 166 patients admitted to the 
hospital during the observation pe-
riod were discharged with no further 
complications.
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